Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 32320766.
- Also identified by DOI 10.1016/j.jaad.2020.04.058.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The use of the humanized monoclonal anti-programmed cell death 1 antibodies pembrolizumab and nivolumab as potent anticancer therapies is rapidly increasing. However, since their approval, numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from nonspecific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Drug Eruptions
- Immune Checkpoint Inhibitors
- Neoplasms
- Nivolumab